Research programme: mTOR inhibitors - Delos Pharmaceuticals

Drug Profile

Research programme: mTOR inhibitors - Delos Pharmaceuticals

Alternative Names: BC 210; bPT-mTOR series; nPT-mTOR series

Latest Information Update: 02 Nov 2012

Price : $50

At a glance

  • Originator Biotica Technology
  • Developer Delos Pharmaceuticals
  • Class Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 25 Oct 2012 Early research in Aging-related disease in USA (unspecified route)
  • 25 Oct 2012 Research programme licensed to Delos Pharmaceuticals worldwide
  • 08 Aug 2011 mTOR inhibitors programme available for partnering/licensing following completion of preclinical proof-of-concept studies. http://www.biotica.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top